Stoke Therapeutics (STOK) Other Non-Current Liabilities (2021 - 2026)

Stoke Therapeutics has reported Other Non-Current Liabilities for 6 years, with the latest figure at $991000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 47.12% year-over-year to $991000.0; the trailing twelve-month figure through Mar 2026 stood at $991000.0 (down 47.12% YoY), and the FY2025 full-year result was $1.1 million, down 53.95% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $991000.0, down from $1.1 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $4.9 million in Q4 2023, with the low at $959000.0 in Q3 2023.
• Average Other Non-Current Liabilities over 5 years is $2.6 million, with a median of $2.5 million recorded in 2024.
• Year-over-year, Other Non-Current Liabilities plunged 73.43% in 2023 and jumped 218.04% in 2024.
• Tracing STOK's Other Non-Current Liabilities over 5 years: stood at $3.0 million in 2022, then soared by 64.56% to $4.9 million in 2023, then sank by 49.26% to $2.5 million in 2024, then plunged by 53.95% to $1.1 million in 2025, then declined by 13.15% to $991000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $991000.0 (Q1 2026), $1.1 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.

Peer Comparison